New Data Announced from Ph 1b/2 EPCORE® CLL-1 Trial of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
“Patients with Richter transformation, an aggressive form of lymphoma, have limited treatment options and face a poor prognosis,” said Arnon Kater, M.D., Ph.D., Department of Hematology, Amsterdam UMC. “The response and survival rates observed in this trial evaluating epcoritamab as a monotherapy treatment are encouraging, especially as a potential option for patients with Richter transformation.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.